175 related articles for article (PubMed ID: 21971215)
1. Sequential administration of bovine and human adenovirus vectors to overcome vector immunity in an immunocompetent mouse model of breast cancer.
Tandon M; Sharma A; Vemula SV; Bangari DS; Mittal SK
Virus Res; 2012 Jan; 163(1):202-11. PubMed ID: 21971215
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model.
Sharma A; Bangari DS; Tandon M; Pandey A; HogenEsch H; Mittal SK
Virology; 2009 Mar; 386(1):44-54. PubMed ID: 19211122
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of innate immunity and vector toxicity following inoculation of bovine, porcine or human adenoviral vectors in a mouse model.
Sharma A; Bangari DS; Tandon M; Hogenesch H; Mittal SK
Virus Res; 2010 Oct; 153(1):134-42. PubMed ID: 20659505
[TBL] [Abstract][Full Text] [Related]
4. Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: implications in gene therapy.
Moffatt S; Hays J; HogenEsch H; Mittal SK
Virology; 2000 Jun; 272(1):159-67. PubMed ID: 10873758
[TBL] [Abstract][Full Text] [Related]
5. Persistence and the state of bovine and porcine adenoviral vector genomes in human and nonhuman cell lines.
Sharma A; Bangari DS; Vemula SV; Mittal SK
Virus Res; 2011 Nov; 161(2):181-7. PubMed ID: 21864589
[TBL] [Abstract][Full Text] [Related]
6. Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus.
Singh N; Pandey A; Jayashankar L; Mittal SK
Mol Ther; 2008 May; 16(5):965-71. PubMed ID: 18301400
[TBL] [Abstract][Full Text] [Related]
7. Bovine adenovirus type 3 internalization is independent of primary receptors of human adenovirus type 5 and porcine adenovirus type 3.
Bangari DS; Sharma A; Mittal SK
Biochem Biophys Res Commun; 2005 Jun; 331(4):1478-84. PubMed ID: 15883040
[TBL] [Abstract][Full Text] [Related]
8. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype.
Mack CA; Song WR; Carpenter H; Wickham TJ; Kovesdi I; Harvey BG; Magovern CJ; Isom OW; Rosengart T; Falck-Pedersen E; Hackett NR; Crystal RG; Mastrangeli A
Hum Gene Ther; 1997 Jan; 8(1):99-109. PubMed ID: 8989999
[TBL] [Abstract][Full Text] [Related]
9. CTLA4Ig delivered by high-capacity adenoviral vector induces stable expression of dystrophin in mdx mouse muscle.
Jiang Z; Schiedner G; Gilchrist SC; Kochanek S; Clemens PR
Gene Ther; 2004 Oct; 11(19):1453-61. PubMed ID: 15269713
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic T lymphocyte responses to proteins encoded by heterologous transgenes transferred in vivo by adenoviral vectors.
Song W; Kong HL; Traktman P; Crystal RG
Hum Gene Ther; 1997 Jul; 8(10):1207-17. PubMed ID: 9215738
[TBL] [Abstract][Full Text] [Related]
11. The effect of adenovirus-specific antibodies on adenoviral vector-induced, transgene product-specific T cell responses.
Small JC; Haut LH; Bian A; Ertl HC
J Leukoc Biol; 2014 Nov; 96(5):821-31. PubMed ID: 25082150
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses.
Sharma A; Tandon M; Ahi YS; Bangari DS; Vemulapalli R; Mittal SK
Gene Ther; 2010 May; 17(5):634-42. PubMed ID: 20164856
[TBL] [Abstract][Full Text] [Related]
13. Longevity of adenovirus vector immunity in mice and its implications for vaccine efficacy.
Sayedahmed EE; Kumari R; Shukla S; Hassan AO; Mohammed SI; York IA; Gangappa S; Sambhara S; Mittal SK
Vaccine; 2018 Oct; 36(45):6744-6751. PubMed ID: 30266488
[TBL] [Abstract][Full Text] [Related]
14. A New Gorilla Adenoviral Vector with Natural Lung Tropism Avoids Liver Toxicity and Is Amenable to Capsid Engineering and Vector Retargeting.
Lu ZH; Dmitriev IP; Brough DE; Kashentseva EA; Li J; Curiel DT
J Virol; 2020 May; 94(10):. PubMed ID: 32102889
[TBL] [Abstract][Full Text] [Related]
15. Current strategies and future directions for eluding adenoviral vector immunity.
Bangari DS; Mittal SK
Curr Gene Ther; 2006 Apr; 6(2):215-26. PubMed ID: 16611043
[TBL] [Abstract][Full Text] [Related]
16. Biology of E1-deleted adenovirus vectors in nonhuman primate muscle.
Zoltick PW; Chirmule N; Schnell MA; Gao GP; Hughes JV; Wilson JM
J Virol; 2001 Jun; 75(11):5222-9. PubMed ID: 11333904
[TBL] [Abstract][Full Text] [Related]
17. Comparative transduction efficiencies of human and nonhuman adenoviral vectors in human, murine, bovine, and porcine cells in culture.
Bangari DS; Shukla S; Mittal SK
Biochem Biophys Res Commun; 2005 Feb; 327(3):960-6. PubMed ID: 15649439
[TBL] [Abstract][Full Text] [Related]
18. Adenoviral vector immunity: its implications and circumvention strategies.
Ahi YS; Bangari DS; Mittal SK
Curr Gene Ther; 2011 Aug; 11(4):307-20. PubMed ID: 21453277
[TBL] [Abstract][Full Text] [Related]
19. Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice.
Dicks MD; Spencer AJ; Coughlan L; Bauza K; Gilbert SC; Hill AV; Cottingham MG
Sci Rep; 2015 Nov; 5():16756. PubMed ID: 26576856
[TBL] [Abstract][Full Text] [Related]
20. An immunomodulatory procedure that stabilizes transgene expression and permits readministration of E1-deleted adenovirus vectors.
Kuzmin AI; Galenko O; Eisensmith RC
Mol Ther; 2001 Mar; 3(3):293-301. PubMed ID: 11273770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
